Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colloidal Silver Antibiotic Superiority Claims Barred Under FTC Settlement

This article was originally published in The Tan Sheet

Executive Summary

A Web site operator has been barred from representing colloidal silver as "superior to antibiotics in killing disease-causing organisms" or treating burns absent reliable scientific evidence, according to a Federal Trade Commission consent order

You may also be interested in...



Raw Health In Violation Of FTC Order, Could Face Monetary Penalties – DoJ

North Carolina-based dietary supplement marketer Raw Health has continued to make unsubstantiated marketing claims in violation of a 2002 Federal Trade Commission order, resulting in a civil complaint by the Department of Justice, FTC announced Sept. 2

Raw Health In Violation Of FTC Order, Could Face Monetary Penalties – DoJ

North Carolina-based dietary supplement marketer Raw Health has continued to make unsubstantiated marketing claims in violation of a 2002 Federal Trade Commission order, resulting in a civil complaint by the Department of Justice, FTC announced Sept. 2

Raw Health In Violation Of FTC Order, Could Face Monetary Penalties – DoJ

North Carolina-based dietary supplement marketer Raw Health has continued to make unsubstantiated marketing claims in violation of a 2002 Federal Trade Commission order, resulting in a civil complaint by the Department of Justice, FTC announced Sept. 2

Related Content

Topics

UsernamePublicRestriction

Register

PS093686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel